Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04793958 · ClinicalTrials.gov registry record · Phase 3

Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)

A Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Mirati Therapeutics.

Active
Registry status
Phase 3
Development phase
461
Enrollment target
20
Study locations

NCT04793958: Active Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, sponsored by Mirati Therapeutics.

NCT04793958 is a Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer that is active but no longer recruiting, run by Mirati Therapeutics. The registered enrollment target is 461 participants, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (162% higher). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04793958, a Phase 3 study of Metastatic Colorectal Cancer and Advanced Colorectal Cancer, is active but no longer recruiting, sponsored by Mirati Therapeutics.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
461 participants
Enrollment target
20
Study locations

Study Summary

Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

Primary Outcome

Defined as time from date of randomization to date of death due to any cause.

Conditions Studied

Metastatic Colorectal Cancer Advanced Colorectal Cancer

Interventions

  • BIOLOGICAL Cetuximab
  • DRUG FOLFIRI Regimen
  • DRUG MRTX849
  • DRUG mFOLFOX6 Regimen

Study Locations (20)

California

  • Local Institution - 010-573 - Bakersfield
  • Local Institution - 010-979C - Chula Vista
  • Local Institution - 010-980 - Fresno
  • Local Institution - 010-851 - Fullerton
  • Local Institution - 010-979A - La Mesa
  • Local Institution - 010-958A - Los Angeles
  • Local Institution - 010-958 - Los Angeles
  • Local Institution - 010-551 - Los Angeles
  • Local Institution - 010-847 - Newport Beach

Alabama

  • Local Institution - 010-855-E - Alabaster
  • Local Institution - 010-855-B - Bessemer
  • Local Institution - 010-855-D - Birmingham
  • Local Institution - 010-855-A - Birmingham
  • Local Institution - 010-855-F - Birmingham
  • Local Institution - 010-855-C - Birmingham
  • Local Institution - 010-855 - Birmingham

Arizona

  • Local Institution - 010-996 - Gilbert
  • Local Institution - 010-566 - Goodyear
  • Local Institution - 010-989 - Phoenix

Arkansas

  • Local Institution - 010-978 - Springdale

Trial Details

FieldValue
Enrollment Target 461 participants
Start Date 2021-06-24
Est. Completion 2026-01-30
Phase Phase 3
Mirati Therapeutics

49 total trials

What the registry record for NCT04793958 still lists

NCT04793958 is an interventional study that assigns participants to a tested intervention. The registered 461 participants enrollment target is mid-sized for trials with a published cap, above the 176-participant average among 45 other Metastatic Colorectal Cancer trials with a reported enrollment target (162% higher).

The record links to 2 conditions, with Metastatic Colorectal Cancer appearing as the primary indexed condition, and to 4 interventions - of which Cetuximab is the first listed.

NCT04793958 names 20 study sites across 4 states, led by California, Alabama, Arizona.

Frequently Asked Questions

What is clinical trial NCT04793958 about?

NCT04793958 is a clinical study titled "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)". Study CA239-0006 is an open-label, randomized Phase 3 clinical trial comparing the efficacy of MRTX849 administered in combination with cetuximab versus chemotherapy in the second-line treatment setting in patients with CRC with KRAS G12C mutation.

What is the current status of trial NCT04793958?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 461 participants. The study started on 2021-06-24. Estimated completion is 2026-01-30.

What conditions does trial NCT04793958 study?

This clinical trial studies the following conditions: Metastatic Colorectal Cancer, Advanced Colorectal Cancer.

What interventions are being tested in trial NCT04793958?

The interventions under investigation include: Cetuximab (BIOLOGICAL), FOLFIRI Regimen (DRUG), MRTX849 (DRUG), mFOLFOX6 Regimen (DRUG).

Who is sponsoring clinical trial NCT04793958?

This trial is sponsored by Mirati Therapeutics, which has 49 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04793958 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Metastatic Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04793958's enrollment target sits among peer trials

461 5th of 45 higher than 41 of 45 other Metastatic Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04546399 · 461 participants · Phase 2

    A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)

  • NCT00949819 · 462 participants

    Active Surveillance for Cancer of the Prostate (ASCaP)

  • NCT05126277 · 462 participants · Phase 3

    Safety, Efficacy and Tolerability of Ianalumab Versus Placebo, Combination With SoC Therapy, in Participants With Active Lupus Nephritis

  • NCT02977780 · 460 participants · Phase 2

    INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT04793958, the US trial registry maintained by the National Library of Medicine. NCT04793958 (mid enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.